International Journal of Research in MEDICAL SCIENCE

ISSN Print: 2664-8733
ISSN Online: 2664-8741
IJRMS 2024; 6(1): 107-109
www.medicalpaper.net
Received: 19-02-2024
Accepted: 22-03-2024

Tessy Augustine
Specialist Paediatrician, Department of Paediatric Haematology and Oncology, Mediclinic City Hospital, Dubai, UAE

Corresponding Author:
Tessy Augustine
Specialist Paediatrician, Department of Paediatric Haematology and Oncology, Mediclinic City Hospital, Dubai, UAE

Optimizing outcomes in Philadelphia-positive acute B-cell leukemia: The role of early imatinib introduction in sustaining remission and minimizing relapse risk

Tessy Augustine

DOI: https://doi.org/10.33545/26648733.2024.v6.i1b.61

Abstract
Philadelphia chromosome-positive acute B-cell leukemia (Ph+ B-ALL) represents a formidable clinical challenge due to its aggressive nature and propensity for relapse. The advent of imatinib, a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein, has reshaped therapeutic paradigms in hematologic malignancies. Despite its established efficacy in chronic myeloid leukemia (CML), the optimal integration of imatinib into frontline therapy for Ph+ B-ALL remains a subject of ongoing investigation. This review synthesizes current evidence to evaluate the impact of early imatinib initiation on achieving sustained complete remission (CR) and mitigating relapse risk in Ph+ B-ALL. We delve into the molecular underpinnings of Ph+ B-ALL, elucidate the rationale for incorporating imatinib upfront, and critically assess clinical studies supporting its use. Furthermore, we explore mechanisms of imatinib resistance, discuss strategies to enhance treatment efficacy, and propose avenues for future research. By providing a nuanced understanding of the role of early imatinib therapy, this review aims to inform therapeutic decision-making and drive improvements in outcomes for patients with Ph+ B-ALL.

Keywords: Specialist Paediatrician, department of paediatric haematology and oncology, Mediclinic City hospital, Dubai, UAE

Introduction
Philadelphia chromosome-positive acute B-cell leukemia (Ph+ B-ALL) represents a distinct molecular subtype of B-ALL characterized by the presence of the Philadelphia chromosome, resulting from the fusion of the BCR and ABL genes. This fusion gives rise to a constitutively active BCR-ABL tyrosine kinase, driving leukemogenesis and conferring resistance to conventional chemotherapy. Historically, Ph+ B-ALL has been associated with poor outcomes, including high rates of relapse and inferior survival compared to Ph-negative B-ALL.

The development of imatinib, a potent inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the treatment landscape for hematologic malignancies, particularly chronic myeloid leukemia (CML). Imatinib exerts its therapeutic effects by disrupting aberrant signaling pathways downstream of BCR-ABL, leading to inhibition of leukemic cell proliferation and induction of apoptosis. While initially explored in the context of relapsed or refractory Ph+ B-ALL, the potential benefits of early imatinib introduction in frontline therapy are increasingly recognized. The chronological progression of treatment options for PH + ALL, spanning from the original implementation of chemotherapy to the present-day use of immunotherapy, is shown in Fig 1.



Fig 1: Timeline of the development of PH + ALL targeted therapy

Molecular Basis of Ph+ B-ALL

The pathogenesis of Ph+ B-ALL is rooted in the dysregulated activation of signaling pathways downstream of the BCR-ABL fusion protein. Constitutive tyrosine kinase activity promotes cell survival, proliferation, and resistance to apoptosis, driving the expansion of leukemic clones. In addition to BCR-ABL, other genetic alterations and microenvironmental factors contribute to disease progression and therapy resistance, highlighting the complexity of Ph+ B-ALL biology.

The Philadelphia chromosome (PH) is distinguished by the t(9;22)(q34;q11) translocation, resulting in the creation of a fusion gene known as BCR-ABL1. This chromosomal anomaly is prevalent in adult acute lymphoblastic leukemia (ALL), affecting 15-25% of adults. Its occurrence rises with age, constituting almost 50% of ALL patients aged 60 years and above [1, 2]. Before the advent of TKIs, patients with PH + ALL had just one opportunity for long-term survival by undergoing HSCT. The introduction of TKIs like Imatinib has led to a significant improvement in the overall survival (OS) rate for patients with PH + ALL, increasing it from 20% to 70% [3, 4]. Subsequently, the subsequent iterations of TKIs, namely Dasatinib and Ponatinib, have shown heightened and expedited molecular reactions. Ponatinib, being a third-generation tyrosine kinase inhibitor (TKI), has shown efficacy in addressing mutations within the ABL1 domain, such as T315I. Next-generation TKIs have shown stronger inhibition of ABL kinase, making low dosage chemotherapy or chemotherapy-free regimens more effective and safer for inducing treatment, particularly in elderly or weak patients. The treatment landscape of PH + ALL is undergoing significant changes because to the progress made in immunotherapy and targeted therapy [5-7]. Ph + Acute lymphoblastic leukemia (ALL) is distinguished by atypical proliferation and compromised differentiation of B cells during the pre-B stage, as well as aberrant expression of leukemia-specific surface antigens such as CD19, CD20, and CD22. These characteristics render PH +ALL a promising candidate for immunotherapeutic intervention. To address this deficiency, Blinatumomab, Inotuzumab Ozogamicin, and CAR-T have been created [2, 8]. In conjunction with immunotherapy, the clinical effectiveness of innovative oral targeted medicines such as Venetoclax and Histone deacetylase inhibitors (HDACi) in conjunction with tyrosine kinase inhibitors (TKIs) is now being assessed for the treatment of refractory relapse (R/R) PH + ALL. This approach signifies a novel avenue of investigation with the objective of attaining more profound remissions via the induction of endogenous apoptosis in cells and the reinstatement of tumor suppressive gene expression.

Rationale for Early Imatinib Introduction

The rationale for incorporating imatinib into frontline therapy for Ph+ B-ALL stems from its ability to target the underlying molecular driver of disease. By promptly inhibiting BCR-ABL activity, imatinib can rapidly induce cytoreduction, enhance the efficacy of conventional chemotherapy, and potentially eradicate residual leukemic cells. Early imatinib administration aims to achieve deep and durable responses, thereby minimizing the risk of relapse and improving long-term outcomes.

Clinical Evidence Supporting Early Imatinib Therapy

Clinical studies evaluating the efficacy of early imatinib introduction in Ph+ B-ALL have yielded promising results. Trials assessing imatinib in combination with standard chemotherapy regimens have demonstrated high rates of complete remission (CR) and prolonged event-free survival (EFS) compared to historical controls. Furthermore, molecular monitoring techniques have provided insights into the depth of response and its correlation with long-term outcomes, highlighting the importance of achieving molecular remission.

Mechanisms of Imatinib Resistance

Despite its efficacy, imatinib resistance remains a significant challenge in the management of Ph+ B-ALL. Mechanisms of resistance include BCR-ABL mutations, activation of alternative signaling pathways, and microenvironment-mediated drug evasion. Strategies to overcome resistance include dose optimization, combination therapy, and the development of next-generation tyrosine kinase inhibitors (TKIs) with improved potency and selectivity.

Future Directions and Concluding Remarks

The integration of imatinib into frontline therapy represents a promising approach to improve outcomes in Ph+ B-ALL. Future research endeavors should focus on refining treatment algorithms, identifying predictive biomarkers of response, and exploring novel therapeutic strategies to overcome resistance. By harnessing the full potential of imatinib and other targeted agents, we can strive towards achieving durable remissions and transforming the prognosis of Ph+ B-ALL.

In conclusion, early introduction of imatinib in the management of Ph+ B-ALL holds considerable promise in sustaining complete remission and minimizing the risk of relapse. Through a multidisciplinary approach encompassing molecular biology, clinical trials, and translational research, we can optimize treatment strategies and pave the way for improved outcomes in this challenging hematologic malignancy.

Conflict of Interest

Not available

Financial Support

Not available

References

1. Leoni V, Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica. 2015;100:295-299. doi:10.3324/haematol.2015.124016
2. Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4:1413-1420. doi:10.1001/jamaoncol.2018.1915
3. Bassan R, Rossi G, Pogliani EM, *et al*. Underuse of anthracyclines in women with HER2-positive advanced breast cancer. J Clin Oncol. 2010;28:1120-11120.
4. Chalandon Y, Thomas X, Hayette S, *et al*. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lympho-blastic leukemia. Blood. 2015;125:3711-3719.
5. Jones D, Thomas D, Yin CC, *et al*. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer.
6. Xu N, Li YL, Li X, *et al*. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2016;9:40. doi:10.1186/s13045-016-0270-5.
7. Brown PA, Shah B, Advani A, *et al*. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1079-1109. doi:10.6004/jnccn.2021.0042
8. Wei AH, Ribera JM, Larson RA, *et al*. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021;35:2220-2231. doi:10.1038/s41375-020-01089-x

How to Cite This Article
Augustine T. Optimizing outcomes in Philadelphia-positive acute b-cell leukemia: The role of early imatinib introduction in sustaining remission and minimizing relapse risk. International Journal of Research in Medical Science. 2024;6(1):107-109.